June 5th, Legend Biotech was listed in Nasdaq, with about $423.8 million has been raised.

 

Morgan Stanley, J.P. Morgan and Jefferies were underwriters in the deal.

 

Cooley LLP, JunHe LLP were legal advisors to issuer on U.S. laws and PRC laws respectively. Cooley was led by partners Divakar Gupta, Richard Segal, Robert Phillips, Will Cai, Michael Yu and Patrick Loofbourrow. The JunHe team was led by partners Wang Yi and Li Chenliang.

 

Davis Polk & Wardwell LLP, Jingtian & Gongcheng were legal advisors to underwriters on U.S. laws and PRC laws respectively. The Davis Polk team included partners Richard D. Truesdell Jr. and Chu Yang, with assistance from partners Patrick E. Sigmon and David R. Bauer.

 

The company’s controlling shareholder GenScript was represented by Jones Day. Harney Westwood & Riegels acted as Cayman Islands legal counsel. Partners Charles Chau and Alan Seem led the Jones Day team. Meanwhile, the Harneys team was led by Partner Raymond Ng.

 

Ernst & Young Hua Ming LLP was the auditor and reporting accountants in the deal.

 

Founded in 2014, Legend Biotech is a Nanjing-based company focusing on cell therapies for oncology and other indications. The company is owned by Hong Kong-listed Genscript Biotech.